All articles by mrinmoyee hazarika
mrinmoyee hazarika
BioCryst gains marketing authorisation for Orladeyo in Chile
The safety and effectiveness of the drug prophylaxis for acute HAE attacks are yet to be proved.
UK to provide up to £39m for AMR research
Up to £24m will be used to strengthen the UK’s collaboration with CARB-X.
EMA validates Sobi’s marketing authorisation application for efanesoctocog alfa
Efanesoctocog alfa is a FVIII therapy that has been developed to treat haemophilia A.
FDA accepts resubmission of Ardelyx’s NDA for XPHOZAH
The resubmitted NDA is based on a comprehensive development programme that includes three Phase III trials of XPHOZAH.
LAPIX receives US patent for LPX-TI641 to treat autoimmune diseases
LPX-TI641 is being developed to treat neuro-autoimmune indications including multiple sclerosis.
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
Elevar submits new drug application for uHCC combo therapy
Rivoceranib is an oral TKI, while camrelizumab is a PD-1 inhibitor.
AGC Biologics rolls out new viral vector platforms
A group of scientists designed BravoAAV and ProntoLVV at AGC Biologics’ site in Milan, Italy.
MIF invests in Nectin to investigate multiple myeloma drug candidate
NTX1088 is Nectin’s lead immunotherapy drug candidate that targets a major immune checkpoint, PVR, also called CD155.
Scribe and Prevail partner for CRISPR-based genetic medicines
Under the deal, Prevail obtains exclusive rights to use Scribe’s CRISPR X-Editing technologies to develop the medicines.
Juno Pharmaceuticals buys Omega Laboratories
The merged entity represents one of the biggest specialist generic injectable operations in Canada.